Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older.

addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial launch in the U.S. in the first half of 2025. A Tropical Disease Priority Review Voucher was ...

A common proposal for prevention of chikungunya and dengue fever in the state has been brought out by the Directorate of Public Health. A common proposal for prevention of chikungunya and dengue ...

which the company said “[addresses] an unmet need for chikungunya prevention for younger travellers”. The FDA’s decision on Vimkunya was supported by positive results from two late-stage clinical ...